Bianchi Porro G, Parente F
J Clin Gastroenterol. 1992 Apr;14(3):192-8.
Topically active agents (i.e., colloidal bismuth subcitrate and sucralfate) have proved to be effective in promoting the healing of both gastric and duodenal ulcers and in relieving ulcer symptoms. Sucralfate alone has also been shown to maintain peptic ulcers in remission when taken continuously for a long period of time, whereas successful short-term therapy with bismuth subcitrate is associated with a more prolonged remission of duodenal ulcer disease when compared to H2 blockers. The antiulcer efficacy of these agents is partially counteracted by the need for multiple daily administrations, which requires greater patient compliance than with H2 antagonists. A specific subgroup of patients who might particularly benefit from these drugs are those with duodenal ulcer resistant to H2 blockers, whereas chronic nonsteroidal antiinflammatory drug users with peptic ulcer respond to therapy with site-protective agents as well as to antisecretory drugs.
局部活性药物（即枸橼酸铋钾和硫糖铝）已被证明在促进胃溃疡和十二指肠溃疡的愈合以及缓解溃疡症状方面有效。单独使用硫糖铝长期持续服用也已显示可维持消化性溃疡处于缓解状态，而与H2受体阻滞剂相比，枸橼酸铋钾短期治疗成功后十二指肠溃疡疾病的缓解期更长。这些药物的抗溃疡疗效因需要每日多次给药而部分抵消，这比使用H2拮抗剂需要患者有更高的依从性。可能特别受益于这些药物的特定患者亚组是那些对H2受体阻滞剂耐药的十二指肠溃疡患者，而患有消化性溃疡的慢性非甾体抗炎药使用者对黏膜保护剂治疗以及抗分泌药物治疗均有反应。
